Drospirenone drug: A drug drospirenone in the form of 1 tablet / d from 14 mm follicle till hCG trigger day
Cetrorelix 0.25 mg: Cetrorelix a drug injection daily sc. from 14 mm follicle till hCG trigger day
Study summary
Participants will:
* Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections
* Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study)
* Have a frozen embryo transferred in a later cycle
* Complete two short questionnaires about their treatment experience - once before starting the injections/pills, and once after the stimulation phase ends
* Be followed to determine if the embryo transfer results in a pregnancy
Eligibility
Sex
FEMALE
Min age
20 Years
Max age
42 Years
Healthy volunteers
No
Inclusion Criteria:
* Spontaneous menstrual cycles (21-35 days)
* Poor ovarian response per Bologna criteria (≥2 of 3): advanced age ≥40 or risk factor for POR; previous poor response (≤3 oocytes with conventional stimulation); abnormal ovarian reserve (AFC \<7 or AMH \<1.1 ng/mL)
* POSEIDON group recorded at enrollment (1-4) for stratified randomization and pre-specified subgroup description - corrects a known limitation of Bologna-only classification, which pools biologically distinct POR phenotypes
* Indication for IVF/ICSI
* Willing and able to undergo mandatory freeze-all/FET protocol
* Signed informed consent, including explicit acknowledgment that fresh transfer is not offered in either study arm
Exclusion Criteria:
* Contraindication to ovarian stimulation
* Known müllerian anomaly
* Uncontrolled systemic disease
* 5 prior failed IVF attempts
* Known contraindication to drospirenone (per product labeling, e.g., renal impairment, adrenal insufficiency, conditions predisposing to hyperkalemia)
Primary outcome measure(s)
Metaphase II (Mii) oocytes — Day 0 Number of mature (MII) oocytes retrieved between drospirenone-PPOS and GnRH antagonist protocols, both using a unified flexible start (leading follicle 14mm), in POR patients undergoing a mandatory freeze-all strategy,
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.